General Information of Drug (ID: DM2JYQA)

Drug Name
S109 Drug Info
Synonyms
oxapium iodide; 6577-41-9; Cyclonium; Cyclonium iodide; UNII-682380CG4N; SH 100; 682380CG4N; DSSTox_CID_26925; DSSTox_RID_82021; DSSTox_GSID_46925; Esperan; Oxapii iodidum; Ciclonium iodide; Iodure d'oxapium; Ioduro de oxapio; 1-[(2-cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl]-1-methylpiperidin-1-ium;iodide; CAS-6577-41-9; NCGC00181356-01; Oxapium iodide [INN:JAN]; Oxapii iodidum [INN-Latin]; C22H34INO2; Iodure d'oxapium [INN-French]; Ioduro de oxapio [INN-Spanish]; ANC 113; Espalexan (TN); Oxapium iodide (JP17/INN); SCHEMBL1316687; CHEMBL2107009; DTXSID6046925; s109; Tox21_112814; 2-Cyclohexyl-2-phenyl-4-piperidinomethyl-dioxolane-1,3 methiodide; AC-669; AKOS015969034; Tox21_112814_1; VA11456; N-Methyl-N-(2-cyclohexyl-2-phenyl-1,3 dioxolan-4-yl-methyl)-piperidinium iodide; NCGC00181356-02; DB-080725; FT-0656107; D01815; Q10859610; 1-((2-Cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methylpiperidin-1-ium iodide; 1-((2-Cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methylpiperidinium iodide; Piperidinium, 1-((2-cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methyl-, iodide
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
PubChem CID
168884
CAS Number
CAS 6577-41-9
TTD Drug ID
DM2JYQA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug(s) Targeting Exportin-1 (XPO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selinexor DMBD4K3 Multiple myeloma 2A83 Phase 3 [3]
Selinexor oral DMDLOBZ Recurrent glioblastoma 2A00.00 Phase 2 [4]
Eltanexor oral DM7CLEZ Colorectal cancer 2B91.Z Phase 1/2 [5]
SL-801 DMIVGYK Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
KOS-1815 DMCGFY6 Solid tumour/cancer 2A00-2F9Z Preclinical [3]
Octahydrocurcumin DMUFDR6 Solid tumour/cancer 2A00-2F9Z Investigative [6]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Exportin-1 (XPO1) TTCJUR4 XPO1_HUMAN Inhibitor [2]

References

1 CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells. Korean J Physiol Pharmacol. 2016 Mar;20(2):161-8.
2 Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-B signaling pathway. Cancer Cell Int. 2020 Mar 30;20:97.
3 Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021 Jan;20(1):21-38.